Daniel Sherbet, MD
Cardiovascular Disease · Little Rock, ARNPI 1558572552
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,448 of the $11,205 with a category attached, or 75.4%. 21 manufacturers reported payments, led by Abbott at 52.1% of the total. Reporting peaked in 2023 at $4,168 and has fallen 56.2% since, to $1,828 in 2025.
Across 143 payments — averaging $78.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Abiomed$2K
- Boston Scientific$1K
- Philips North America LLC$621
- Shockwave Medical, Inc$513
- Avinger Inc.$255
- plus $877 from 15 others
Across 37 payments — averaging $2146.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$71K
- Abbott$8K
- Abiomed$319
What the payments were for
- Travel & lodging$2,75825%
- Food & beverage$8,44875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 82 | $5,841 |
| Abiomed | 6 | $2,096 |
| Boston Scientific | 13 | $1,001 |
| Philips North America LLC | 4 | $621 |
| Shockwave Medical, Inc | 4 | $513 |
| Avinger Inc. | 3 | $255 |
| Livanova USA, Inc. | 2 | $165 |
| Novartis | 10 | $142 |
| Merck | 3 | $128 |
| Teleflex LLC | 1 | $98 |
| Penumbra, Inc. | 1 | $66 |
| Asahi Intecc USA, Inc. | 2 | $64 |
| AstraZeneca | 3 | $40 |
| Pfizer | 2 | $30 |
| Inari Medical, Inc. | 1 | $28 |
| Cordis US CORP. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$2,026
- ENSITE PRECISION$904
- CARDIOMEMS$671
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$493
- AMPLATZER AMULET$492
- (6575) Coronary Undivided$426
- AVEIR$398
- EnSite Precision Cardiac Mapping System$377
- COROFLOW$270
- Farapulse$258
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$236
- PANTHERIS$218
- OPTIS$204
- Absorb GT1$185
- CardioMEMS HF System$152
- HORNET$150
- LifeSPARC System$146
- TactiCath Quartz CFA Catheter$132
- WATCHMAN Access System$130
- ENSITE$126
How this compares
$11,205 in reported general payments places this provider in the 80th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 473 | $380,675 |
| EntrestoSacubitril/Valsartan | 185 | $192,555 |
| FarxigaDapagliflozin Propanediol | 112 | $88,830 |
| Repatha SureclickEvolocumab | 89 | $81,192 |
| XareltoRivaroxaban | 86 | $79,436 |
| Dofetilide | 75 | $21,000 |
| Repatha SyringeEvolocumab | 37 | $19,946 |
| Praluent PenAlirocumab | 14 | $15,885 |
| JardianceEmpagliflozin | 12 | $11,717 |
| MultaqDronedarone Hcl | 12 | $9,256 |
| Metoprolol Succinate | 785 | $9,076 |
| Atorvastatin Calcium | 1,038 | $9,053 |
| Bumetanide | 175 | $7,097 |
| Rosuvastatin Calcium | 439 | $6,017 |
| Ranolazine ErRanolazine | 80 | $5,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $30 | $380,675473 claims |
| NovartisEntresto | $142 | $192,555185 claims |
| AstraZenecaFarxiga | $40 | $88,830112 claims |
| Johnson & JohnsonXarelto | $17 | $79,43686 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.